209 related articles for article (PubMed ID: 27091805)
21. Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab.
Owosho AA; Randazzo J; Rosen EB; Estilo CL; Huryn JM; Chi P; Yom SK
Oral Oncol; 2016 Dec; 63():e1-e3. PubMed ID: 27743938
[No Abstract] [Full Text] [Related]
22. Pembrolizumab-Induced Alopecia Areata.
Elshimy N; Blakeway E; Mitra A
Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
[No Abstract] [Full Text] [Related]
23. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
Chiarion Sileni V; MandalĂ M; Queirolo P
Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
[TBL] [Abstract][Full Text] [Related]
24. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
[No Abstract] [Full Text] [Related]
25. [Two cases of granuloma annulare under anti-PD1 therapy].
Charollais R; Aubin F; Roche-Kubler B; Puzenat E
Ann Dermatol Venereol; 2018 Feb; 145(2):116-119. PubMed ID: 29221649
[TBL] [Abstract][Full Text] [Related]
26. Deceleration in the rate of keratinocyte cancers and precancerous lesions during programmed death-1 inhibition therapy for advanced melanoma, with recrudescence on discontinuation.
Roche L; Moriarty B; Fabre A; Crowne J; Lally A
Clin Exp Dermatol; 2022 Mar; 47(3):582-584. PubMed ID: 34633688
[No Abstract] [Full Text] [Related]
27. Acute localised exanthematous pustulosis secondary to pembrolizumab.
Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
[No Abstract] [Full Text] [Related]
28. Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab.
Rickard F; Hyams C; Low AT
BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29735504
[TBL] [Abstract][Full Text] [Related]
29. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
Arianayagam S; Ieremia E; Matin RN
Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
[No Abstract] [Full Text] [Related]
30. PD-1 Blockade-induced Inflammatory Arthritis.
Nobashi T; Mittra E
Radiology; 2018 Dec; 289(3):616. PubMed ID: 30277446
[No Abstract] [Full Text] [Related]
31. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
Donaldson M; Owen JL; Choi JN
JAMA Dermatol; 2018 Jul; 154(7):846-847. PubMed ID: 29800007
[No Abstract] [Full Text] [Related]
32. Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet's-like Infiltrate.
Parekh V; Gangadhar T; Kreider KL; Elenitsas R; Chu EY
JAMA Dermatol; 2017 Jul; 153(7):719-721. PubMed ID: 28445579
[No Abstract] [Full Text] [Related]
33. [Treating metastatic melanoma: Risk management].
Lebbe C; Robert C
Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
[No Abstract] [Full Text] [Related]
34. Arterial thrombosis and anti-PD-1 blockade.
Boutros C; Scoazec JY; Mateus C; Routier E; Roy S; Robert C
Eur J Cancer; 2018 Mar; 91():164-166. PubMed ID: 29289455
[No Abstract] [Full Text] [Related]
35. Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma.
Cho M; Nonomura Y; Kaku Y; Nakabo S; Endo Y; Otsuka A; Kabashima K
J Dermatol; 2019 Jan; 46(1):e43-e44. PubMed ID: 29863795
[No Abstract] [Full Text] [Related]
36. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII.
Wada N; Uchi H; Furue M
J Dermatol; 2017 Oct; 44(10):e240-e241. PubMed ID: 28677843
[No Abstract] [Full Text] [Related]
37. MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma.
Nakahara S; Fukushima S; Okada E; Morinaga J; Kubo Y; Tokuzumi A; Matsumoto S; Tsuruta-Kadohisa M; Kimura T; Kuriyama H; Miyashita A; Kajihara I; Jinnin M; Ihn H
J Dermatol Sci; 2020 Jan; 97(1):77-79. PubMed ID: 31843231
[No Abstract] [Full Text] [Related]
38. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
[No Abstract] [Full Text] [Related]
39. Checkpoint Inhibitor-Induced Hemorrhagic Gastritis with Pembrolizumab.
Rao BB; Robertson S; Philpott J
Am J Gastroenterol; 2019 Feb; 114(2):196. PubMed ID: 30353060
[No Abstract] [Full Text] [Related]
40. Mitochondrial myopathy associated with anti-programmed cell death 1 therapy.
Ibrahim T; Adam C; Routier E; Slama A; Robert C
Eur J Cancer; 2019 Mar; 110():71-73. PubMed ID: 30772655
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]